02704nas a2200217 4500000000100000008004100001653001300042653001200055653003900067653001900106100001800125700001600143700001300159700001200172700001500184245015000199856007700349300001000426490000600436520204400442 2015 d10aResearch10aPoverty10aNeglected tropical diseases (NTDs)10aDisease burden1 aPhilipsborn P1 aSteinbeis F1 aBender M1 aRegmi S1 aTinneman P00aPoverty-related and neglected diseases–an economic and epidemiological analysis of poverty relatedness and neglect in research and development. uhttps://www.tandfonline.com/doi/pdf/10.3402/gha.v8.25818?needAccess=true a15 p.0 v83 a

Background: Economic growth in low- and middle-income countries (LMIC) has raised interest in how disease burden patterns are related to economic development. Meanwhile, poverty-related diseases are considered to be neglected in terms of research and development (R&D).

Objectives: Developing intuitive and meaningful metrics to measure how different diseases are related to poverty and neglected in the current R&D system.

Design: We measured how diseases are related to economic development with the income relation factor (IRF), defined by the ratio of disability-adjusted life-years (DALYs) per 100,000 inhabitants in LMIC versus that in high-income countries. We calculated the IRF for 291 diseases and injuries and 67 risk factors included in the Global Burden of Disease Study 2010. We measured neglect in R&D with the neglect factor (NF), defined by the ratio of disease burden in DALYs (as percentage of the total global disease burden) and R&D expenditure (as percentage of total global health-related R&D expenditure) for 26 diseases.

Results: The disease burden varies considerably with the level of economic development, shown by the IRF (median: 1.38; interquartile range (IQR): 0.79–6.3). Comparison of IRFs from 1990 to 2010 highlights general patterns of the global epidemiological transition. The 26 poverty-related diseases included in our analysis of neglect in R&D are responsible for 13.8% of the global disease burden, but receive only 1.34% of global health-related R&D expenditure. Within this group, the NF varies considerably (median: 19; IQR: 6–52).

Conclusions: The IRF is an intuitive and meaningful metric to highlight shifts in global disease burden patterns. A large shortfall exists in global R&D spending for poverty-related and neglected diseases, with strong variations between diseases.